Ayala Pharmaceuticals, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.
Ayala Pharmaceuticals, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Ayala Pharmaceuticals, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Ayala Pharmaceuticals, Inc. Competitors
Ayala Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans